Share of people with HIV who receive antiretroviral therapy in Libya
Libya: Share of people with HIV who receive antiretroviral therapy was 50.0% in 2023. ▲ Rising
Share of people with HIV who receive antiretroviral therapy in Libya, 2000–2023
Source: UNAIDS estimates, via World Bank (2026) – processed by Our World in Data. Measured in % of people living with HIV.
Analysis
In 2023, share of people with hiv who receive antiretroviral therapy in Libya stood at 50.0%.
The figure is up 6.4% on the previous year and down 2.0% over ten years.
Over the whole period, share of people with hiv who receive antiretroviral therapy in Libya peaked at 68.0% in 2018 and was at its lowest, 12.0%, in 2000.
That places Libya 120th out of 143 countries with data for 2023, putting it in the bottom quarter.
The long-run direction has been consistently rising across the 24 years of available data.
Share of people with HIV who receive antiretroviral therapy in Libya, year by year
| Year | % of people living with HIV | Change |
|---|---|---|
| 2000 | 12.0% | — |
| 2001 | 13.0% | +8.3% |
| 2002 | 15.0% | +15.4% |
| 2003 | 13.0% | -13.3% |
| 2004 | 18.0% | +38.5% |
| 2005 | 20.0% | +11.1% |
| 2006 | 23.0% | +15.0% |
| 2007 | 27.0% | +17.4% |
| 2008 | 32.0% | +18.5% |
| 2009 | 38.0% | +18.8% |
| 2010 | 44.0% | +15.8% |
| 2011 | 50.0% | +13.6% |
| 2012 | 52.0% | +4.0% |
| 2013 | 51.0% | -1.9% |
| 2014 | 55.0% | +7.8% |
| 2015 | 59.0% | +7.3% |
| 2016 | 61.0% | +3.4% |
| 2017 | 62.0% | +1.6% |
| 2018 | 68.0% | +9.7% |
| 2019 | 53.0% | -22.1% |
| 2020 | 50.0% | -5.7% |
| 2021 | 49.0% | -2.0% |
| 2022 | 47.0% | -4.1% |
| 2023 | 50.0% | +6.4% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 21.1% | 12.0% | 38.0% | 10 |
| 2010s | 55.5% | 44.0% | 68.0% | 10 |
| 2020s | 49.0% | 47.0% | 50.0% | 4 |
Countries ranked near Libya
More health data for Libya
- Un projection of annual infant deaths, annual growth rate -1.48 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 1.1 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,084 deaths per 1,000 people (2090)
- Number of infants who die before age 1 133 deaths (2100)
- Population ages 0-14, female, annual growth rate -1.04 % change on previous year (2025)
- Population ages 0-14, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, female, per capita 0.1306 units per person (2025)
- Population ages 0-14, male, annual growth rate -1.02 % change on previous year (2025)
- Population ages 0-14, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 0-14, male, per capita 0.1378 units per person (2025)
Frequently asked questions
- What is share of people with hiv who receive antiretroviral therapy in Libya?
- Share of people with hiv who receive antiretroviral therapy in Libya was 50.0% in 2023, according to UNAIDS estimates, via World Bank (2026) – processed by Our World in Data.
- What is the highest share of people with hiv who receive antiretroviral therapy recorded in Libya?
- The highest recorded value was 68.0% in 2018.
- What is the lowest share of people with hiv who receive antiretroviral therapy recorded in Libya?
- The lowest recorded value was 12.0% in 2000.
- How does Libya rank for share of people with hiv who receive antiretroviral therapy?
- Libya ranks 120th out of 143 countries with data for 2023.
- Is share of people with hiv who receive antiretroviral therapy rising or falling in Libya?
- Over the last ten years it is down 2.0%. The long-run trend across the full record is rising.
- Where does this Libya data come from?
- The figures come from UNAIDS estimates, via World Bank (2026) – processed by Our World in Data, published as part of Share of people with HIV who receive antiretroviral therapy. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 24 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Antiretroviral therapy is a combination of several antiretroviral medicines, used to slow the rate at which HIV multiplies inside the body.